ISEMBYLD (Apitegromab)

ISEMBYLD (apitegromab-mstn), from Scholar Rock, is the first spinal muscular atrophy (SMA) therapy that targets muscle rather than motor neurons. The FDA approved it on 11 September 2026 for adults and children aged 2 years and older with SMA who are already receiving an SMN2-targeted treatment (such as nusinersen or risdiplam).

Apitegromab blocks the activation of myostatin, a natural protein that limits muscle growth, helping preserve and build muscle strength on top of SMN therapy. In the Phase 3 SAPPHIRE trial, 34.2% of treated patients gained at least 3 points on the Hammersmith motor scale (HFMSE) at 52 weeks versus 13.5% on placebo. The recommended dose is 10 mg/kg by IV infusion once every 4 weeks.

• Serious fractures have occurred in treated patients; use with caution in patients with low bone density or a history of multiple fractures.
• The most common side effects include upper respiratory tract infections, vomiting, cough, viral infections, headache, gastroenteritis, pharyngitis and hypersensitivity.
• ISEMBYLD is an add-on therapy and is not intended to replace SMN-targeted treatment.

What documents are required to import ISEMBYLD to India?

ISEMBYLD may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered paediatric or adult neurologist
• Genetic report confirming SMA (SMN1 deletion/mutation) and details of current SMN-targeted therapy
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is ISEMBYLD available in India?

ISEMBYLD was FDA-approved in September 2026 and is not yet available in India. It can be legally accessed through the Named Patient Program (NPP), subject to applicable regulations.

Indian Pharma Network (IPN) can source ISEMBYLD from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For ISEMBYLD cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA-approved — 11 September 2026.
• European Union / Japan: Not approved as of October 2026.

What is ISEMBYLD used for?

ISEMBYLD (apitegromab) is a first-in-class muscle-targeted myostatin inhibitor used for spinal muscular atrophy alongside SMN-targeted treatment.

Who manufactures ISEMBYLD?

ISEMBYLD is from Scholar Rock.

How does ISEMBYLD work?

Apitegromab blocks the activation of myostatin, a natural protein that limits muscle growth, helping preserve and build muscle strength on top of SMN therapy.

Can ISEMBYLD be used without nusinersen or risdiplam?

No. It is approved only as an add-on for patients already receiving an SMN-targeted treatment.

Is ISEMBYLD approved by the US FDA?

Yes. The FDA approved ISEMBYLD on 11 September 2026.